US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Direxion Daily MSCI Emerging Markets Bull 3X Shares

28.82

-0.2600-0.89%

Volume:83.58K

Turnover:2.40M

Market Cap:62.87M

PE:- -

High:28.91

Open:28.46

Low:28.27

Close:29.08

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

Canadian exporters inquire on trade insurance as Trump’s tariffs heighten risk

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EDC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EDC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EDC\",,,,,undefined,":{"symbol":"EDC","market":"US","secType":"STK","nameCN":"Direxion Daily MSCI Emerging Markets Bull 3X Shares","latestPrice":28.82,"timestamp":1745611200000,"preClose":29.08,"halted":0,"volume":83575,"delay":0,"floatShares":2181598,"shares":2181598,"eps":0,"marketStatus":"Pre-Mkt","change":-0.26,"latestTime":"04-28 05:16:44 EDT","open":28.46,"high":28.9074,"low":28.27,"amount":2395358.42244,"amplitude":0.021919,"askPrice":31.5,"askSize":100,"bidPrice":26.11,"bidSize":100,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745847000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":28.82,"sharesOutstanding":2181598,"nav":28.888,"aum":63021608.82,"bidAskSpread":0.001654,"postHourTrading":{"tag":"盘后","latestPrice":28.82,"preClose":28.82,"latestTime":"16:37 EDT","volume":9,"amount":259.38,"timestamp":1745613428364},"volumeRatio":0.7770203686757968,"impliedVol":0.6121,"impliedVolPercentile":0.8876},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EDC\",,,,,undefined,":{"symbol":"EDC","floatShares":2181598,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7770203686757968,"shares":2181598,"dividePrice":1.10206,"high":28.9074,"amplitude":0.021919,"preClose":29.08,"low":28.27,"week52Low":20.13,"pbRate":"--","week52High":41.9399,"institutionHeld":0,"latestPrice":28.82,"eps":0,"divideRate":0.038239,"volume":83575,"delay":0,"ttmEps":0,"open":28.46,"prevYearClose":28.77,"prevWeekClose":28.82,"prevMonthClose":30.72,"prevQuarterClose":30.72,"fiveDayClose":26.07,"twentyDayClose":32.79,"sixtyDayClose":29.63},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EDC\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EDC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529030637","title":"Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2529030637","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529030637?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:25","pubTimestamp":1745411100,"startTime":"0","endTime":"0","summary":"The Company is now preparing for the enrollment of the first patient to receive Clearmind’s innovative treatment as part of the trial. Vancouver, Canada, April 23, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the initiation of its U.S. clinical trial site at the Yale School of Medicine’s Department of Psychiatry. With this initiation, the Company has now activated all planned sites for its clinical trial for its Phase I/IIa clinical trial in Alcohol Use Disorder  and can begin patient enrollment .Clearmind has completed all necessary preparations for the clinical trial, including obtaining Investigational New Drug  approval from the U.S. Food and Drug Administration  to start the Phase I/IIa clinical trial, Institutional Review Board  approvals from each clinical site, launch of its Electronic Data Capture  system to supp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-completes-initiation-alcohol-122500446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","EDC","CMND"],"gpt_icon":0},{"id":"2526661301","title":"Canadian exporters inquire on trade insurance as Trump’s tariffs heighten risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526661301","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526661301?lang=en_us&edition=fundamental","pubTime":"2025-04-12 00:27","pubTimestamp":1744388836,"startTime":"0","endTime":"0","summary":"OTTAWA – A little-known insurance product is gaining traction in Canada as exporters seek to guard against losses and bankruptcies of their suppliers and customers due to U.S. President Donald Trump’s","market":"fut","thumbnail":"https://cloudfront-us-east-1.images.arcpublishing.com/bellmediainc/MTVWZYGEPJANPPIPIG6A62CCVE.JPG","type":0,"news_type":0,"thumbnails":["https://cloudfront-us-east-1.images.arcpublishing.com/bellmediainc/MTVWZYGEPJANPPIPIG6A62CCVE.JPG"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/tariffs/2025/04/11/canadian-exporters-inquire-on-trade-insurance-as-trumps-tariffs-heighten-risk/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["EDC","BK7062","EDC.AU"],"gpt_icon":0},{"id":"2524493820","title":"Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524493820","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524493820?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:30","pubTimestamp":1743597000,"startTime":"0","endTime":"0","summary":"HOUSTON, TX, April 02, 2025  -- Nexalin Technology, Inc.   the leader in Deep Intracranial Frequency Stimulation  of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego , in collaboration with the VA San Diego Healthcare System . The company began treatment of the first patients this week with the Nexalin HALO.The trial follows the recent successful shipment and integration of Nexalin’s HALO Clarity devices at UCSD, where they are being used to provide non-invasive, at-home neurostimulation therapy with AI-integrated remote monitoring. Nexalin’s Electronic Data Capture  platform and Patient Monitoring System  enable real-time tracking of patient adherence and treatment progress. As the study progresses, additional HALO Clarity devices will be deployed to ensure optimal patient coverage and data collection.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexalin-technology-enrolls-first-patients-123000694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","NXLIW","EDC","NXL"],"gpt_icon":0},{"id":"2524113836","title":"Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2524113836","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524113836?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:15","pubTimestamp":1743509700,"startTime":"0","endTime":"0","summary":"The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction Vancouver, Ca","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053342/0/en/Clearmind-Launches-its-EDC-System-to-Support-its-Phase-I-II-Clinical-Trial-of-its-MEAI-Based-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDC"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EDC\",params:#limit:5,,,undefined,":[{"date":"2025-03-25","symbol":"EDC","amount":0.43543,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"新兴市场ETF-Direxion三倍做多","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-12-23","symbol":"EDC","amount":0.12693,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"新兴市场ETF-Direxion三倍做多","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"},{"date":"2024-09-24","symbol":"EDC","amount":0.24602,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-24","defaultRemindTime":1727184600000,"name":"新兴市场ETF-Direxion三倍做多","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-01","payableDate":"2024-09-24","currency":"USD","dateTimestamp":1727150400000,"payDate":"2024-10-01"},{"date":"2024-06-25","symbol":"EDC","amount":0.29368,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"新兴市场ETF-Direxion三倍做多","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"EDC","amount":0.46796,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"新兴市场ETF-Direxion三倍做多","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EDC\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-20","recordDate":"2018-03-21","paymentDate":"2018-03-27","value":0.47048,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.01825,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.52021,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.29138,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-31","value":0.01481,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EDC\",market:\"US\",delay:false,,,undefined,":{}}}